These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 2960643

  • 1. Treatment of infections by staphylococci and other gram-positive bacteria with teicoplanin: an open study.
    Pauluzzi S, Del Favero A, Menichetti F, Baratta E, Moretti VM, Di Filippo P, Pasticci MB, Guerciolini R, Patoia L, Frongillo RF.
    J Antimicrob Chemother; 1987 Sep; 20(3):431-8. PubMed ID: 2960643
    [Abstract] [Full Text] [Related]

  • 2. Teicoplanin in the treatment of infections by staphylococci, Clostridium difficile and other gram-positive bacteria.
    de Lalla F, Santoro D, Rinaldi E, Suter F, Cruciani M, Guaglianone MH, Rizzardini G, Pellegata G.
    J Antimicrob Chemother; 1989 Jan; 23(1):131-42. PubMed ID: 2526109
    [Abstract] [Full Text] [Related]

  • 3. [Teicoplanin and Gram-positive coccus infections. Results of a multicenter study on 66 cases].
    Dureux JB, Canton P, Chavanet P, Chippaux C, Dupeyron JP, Estavoyer JM, Giorgi C, Jaeger A, Jehl F, Kazmierzack A.
    Pathol Biol (Paris); 1987 May; 35(5):511-5. PubMed ID: 2956564
    [Abstract] [Full Text] [Related]

  • 4. A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria.
    Lewis P, Garaud JJ, Parenti F.
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():61-7. PubMed ID: 2965133
    [Abstract] [Full Text] [Related]

  • 5. Teicoplanin monotherapy of serious infections caused by gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial.
    Davey PG, Williams AH.
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():43-50. PubMed ID: 1829076
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy and safety of teicoplanin.
    Stille W, Sietzen W, Dieterich HA, Fell JJ.
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():69-79. PubMed ID: 2965134
    [Abstract] [Full Text] [Related]

  • 7. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
    Bibler MR, Frame PT, Hagler DN, Bode RB, Staneck JL, Thamlikitkul V, Harris JE, Haregewoin A, Bullock WE.
    Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
    [Abstract] [Full Text] [Related]

  • 8. Treatment of bone and soft tissue infections with teicoplanin.
    Marone P, Concia E, Andreoni M, Suter F, Cruciani M.
    J Antimicrob Chemother; 1990 Mar; 25(3):435-9. PubMed ID: 2140111
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria.
    Glupczynski Y, Lagast H, Van der Auwera P, Thys JP, Crokaert F, Yourassowsky E, Meunier-Carpentier F, Klastersky J, Kains JP, Serruys-Schoutens E.
    Antimicrob Agents Chemother; 1986 Jan; 29(1):52-7. PubMed ID: 2942100
    [Abstract] [Full Text] [Related]

  • 11. Teicoplanin in the treatment of skin and soft tissue infections.
    Turpin PJ, Taylor GP, Logan MN, Wood MJ.
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():117-22. PubMed ID: 2965123
    [Abstract] [Full Text] [Related]

  • 12. Therapy of serious gram-positive infections with teicoplanin.
    Davies AJ, Stone JM, Synott M.
    Drugs Exp Clin Res; 1989 Jan; 15(1):29-31. PubMed ID: 2526010
    [Abstract] [Full Text] [Related]

  • 13. Teicoplanin in the treatment of infection caused by gram-positive organisms.
    Williams AH, Grüneberg RN, Webster A, Ridgway GL.
    J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Microbiological-clinical study on the efficacy of a new antibiotic: teicoplanin].
    Martinetto P, Gariglio M, Malcangi A, Cavallo GP.
    G Batteriol Virol Immunol; 1985 Mar; 78(1-6):86-94. PubMed ID: 2943627
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
    LeFrock JL, Ristuccia AM, Ristuccia PA, Quenzer RW, Haggerty PG, Allen JE, Lettau LA, Schwartz R, Appleby D.
    Eur J Surg Suppl; 1992 Mar; (567):9-13. PubMed ID: 1381644
    [Abstract] [Full Text] [Related]

  • 18. Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients.
    Lemerle S, de La Rocque F, Lamy R, Fremaux A, Bernaudin F, Lobut JB, Reinert P.
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():113-6. PubMed ID: 2965122
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of teicoplanin as antimicrobial treatment of severe nosocomial infections caused by gram-positive bacteria: a preliminary study.
    Micozzi A, Venditti M, Brandimarte C, Baiocchi P, Martino P, Serra P.
    Chemioterapia; 1988 Apr; 7(2):101-4. PubMed ID: 2969302
    [Abstract] [Full Text] [Related]

  • 20. Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.
    Kempf P, Pompetzki H, Oppermann A, Wittenberger R, Siebert J, Fell JJ, Dieterich HA.
    Infection; 1989 Apr; 17(3):177-81. PubMed ID: 2525529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.